Allspring Global Investments Holdings LLC Sells 1,603 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Allspring Global Investments Holdings LLC decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 4.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 37,514 shares of the biopharmaceutical company’s stock after selling 1,603 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Alnylam Pharmaceuticals were worth $7,508,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock valued at $1,768,291,000 after buying an additional 126,373 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Alnylam Pharmaceuticals by 3.0% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,997,082 shares of the biopharmaceutical company’s stock valued at $1,020,524,000 after buying an additional 202,916 shares during the last quarter. State Street Corp increased its stake in Alnylam Pharmaceuticals by 2.7% in the 2nd quarter. State Street Corp now owns 2,988,859 shares of the biopharmaceutical company’s stock valued at $435,925,000 after buying an additional 79,369 shares during the last quarter. Invesco Ltd. increased its stake in shares of Alnylam Pharmaceuticals by 8.8% during the 1st quarter. Invesco Ltd. now owns 968,755 shares of the biopharmaceutical company’s stock worth $158,187,000 after purchasing an additional 78,665 shares during the last quarter. Finally, Amundi increased its stake in shares of Alnylam Pharmaceuticals by 3.6% during the 2nd quarter. Amundi now owns 906,534 shares of the biopharmaceutical company’s stock worth $125,593,000 after purchasing an additional 31,584 shares during the last quarter.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $235.53 on Monday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $117.58 and a 52-week high of $242.97. The company has a debt-to-equity ratio of 3.85, a quick ratio of 3.33 and a current ratio of 3.48. The company has a market capitalization of $28.98 billion, a P/E ratio of -24.11 and a beta of 0.50. The company has a fifty day moving average of $224.19 and a 200-day moving average of $203.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last posted its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.86) by ($1.46). Alnylam Pharmaceuticals had a negative return on equity of 430.74% and a negative net margin of 123.02%. The company had revenue of $264.31 million for the quarter, compared to the consensus estimate of $291.81 million. During the same period in the prior year, the firm posted ($1.72) earnings per share. The business’s revenue was up 40.9% on a year-over-year basis. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -9.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ALNY shares. Morgan Stanley decreased their price target on shares of Alnylam Pharmaceuticals from $220.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, October 28th. Barclays reduced their price objective on shares of Alnylam Pharmaceuticals from $240.00 to $236.00 and set an “overweight” rating for the company in a research note on Friday, October 28th. Piper Sandler lifted their price objective on shares of Alnylam Pharmaceuticals from $226.00 to $253.00 and gave the company an “overweight” rating in a research note on Friday, December 16th. StockNews.com started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, Royal Bank of Canada lifted their price objective on shares of Alnylam Pharmaceuticals from $225.00 to $250.00 and gave the company an “outperform” rating in a research note on Tuesday, September 20th. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.06.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.